Detemir Insulin

Diabetes Medication Article

FDA's Role in Regulating Insulin

FDA's Center for Drug Evaluation and Research (CDER) oversees drug products, including insulin. CDER makes sure that drugs sold in the U.S. are safe and effective. The center evaluates new types of insulin products, and it regulates the manufacturing, labeling, and advertising of insulin products.

Companies wanting to market insulin products are responsible for testing their products and submitting data showing they are safe and effective. At CDER, teams of doctors, statisticians, and scientists review new drug applications (NDAs). In some cases, FDA seeks help from advisory committees made up of outside experts.

Once a new insulin product is on the market, CDER monitors its quality and makes sure that its manufacturer follows FDA laws and regulations. CDER also monitors insulin products carefully after they are approved to identify any unexpected side effects. Through a system called MedWatch, health professionals and consumers can report serious adverse reactions to any medical product. CDER collects information from MedWatch and the drug industry and conducts statistical evaluations on drug usage, adverse reactions, poisonings, safety, and effectiveness. If necessary, CDER shares information with patients and health professionals.

Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat

Detemir Insulin News

Detemir insulin

Go to the new RSS page and renew your subscription.]]>

IMPORTANT: Bing News RSS feed has moved!

We report a series of experiments forming a comprehensive characterisation of the long acting insulin analogues, glargine and detemir, in comparison with human insulin, IGF-1, and the super-mitogenic insulin, X10. Methods We measured binding of ligands to ...

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10

Basal/bolus therapy was thus truly introduced for those requiring intensive insulin therapy. Years later, Detemir, a 12-16 hour relatively peakless insulin (given once or twice daily), also was added to the basal insulin group. These two insulins have ...

Degludec: A New Basal Insulin

The annual cost of type 2 diabetes therapy was driven by the uptake of newly approved drugs, such as Actos (pioglitazone) and Avandia (rosiglitazone) until 2006 and the launch of new therapies, such as Levemir (insulin detemir), Byetta (exenatide), Januvia ...